Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-018 for Postoperative Crohn's Disease Recurrence
NCT03943446Phase 2Terminated
- Sponsor
- Takeda
- Start
- Aug 2020
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of sibofimloc in Crohn's disease (3 arms), sponsored by Takeda. Primary endpoint: Percentage of Participants With Endoscopic Recurrence of CD as Assessed by Rutgeerts Grading Scale at 26 weeks. Started Aug 2020; status: terminated.
02
Drugs
sibofimloc
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03943446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943446.